A lot of patients have received complete response (CR) or partial response (PR) under the PI3K/Akt/mTOR inhibitors treatment, providing important indications and possibilities for ESCC therapy (Supplementary Table S2). This evidence concerns the gene MTOR and esophageal squamous cell carcinoma.